文献速递核素与放射性配体治疗放射性药物与辐射防护

[177Lu]Lu-DOTATATE治疗中骨髓特异性摄取导致红骨髓吸收剂量偏高

Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment.
PubMed 文献 · J Nucl Med · 2023-06-08

研究对17例神经内分泌肿瘤患者(其中7例确诊骨转移)在首个[177Lu]Lu-DOTATATE治疗周期后行4次SPECT/CT显像,用蒙特卡洛重建和房室模型区分红骨髓特异性摄取与非特异性血池贡献。结果显示红骨髓特异性摄取平均比非特异性摄取高49%(范围0%-93%),基于血液的剂量学方法低估红骨髓吸收剂量。

要点

  • 17例患者T9-L5椎体及髋骨均见[177Lu]Lu-DOTATATE摄取增高,红骨髓特异性摄取平均较非特异性高49%(范围0%-93%)。
  • 椎体与髋骨红骨髓总吸收剂量中位数分别为0.056±0.023 Gy/GBq和0.043±0.022 Gy/GBq。
  • 骨转移患者椎体与髋骨红骨髓吸收剂量分别为0.085±0.046 Gy/GBq和0.069±0.033 Gy/GBq。

核心结论

  • 结果提示[177Lu]Lu-DOTATATE的红骨髓特异性摄取与骨髓内表达生长抑素受体2型的造血祖细胞观察相符。
  • 基于血液的剂量学方法未能计入特异性摄取的延长消除,低估了红骨髓吸收剂量。

研究设计与样本

  • 17例确诊神经内分泌肿瘤患者接受[177Lu]Lu-DOTATATE治疗,其中7例有确诊骨转移。
  • 首个治疗周期后每例患者在给药后4、24、48和168小时共行4次SPECT/CT显像。
  • 采用蒙特卡洛重建定量肿瘤及推测含红骨髓的多个骨骼部位(T9-L5椎体与髋骨髂骨部分)的活度浓度。
  • 以下行主动脉活度浓度作为房室模型输入,分离非特异性血池贡献与红骨髓特异性活度浓度,并据此对各骨骼部位行红骨髓剂量学估算。

主要发现

  • 全部17例患者T9-L5椎体与髋骨均见[177Lu]Lu-DOTATATE摄取较主动脉活度浓度增高。
  • 红骨髓特异性摄取平均较非特异性摄取高49%(范围0%-93%)。
  • 椎体与髋骨红骨髓总吸收剂量中位数(±SD)分别为0.056±0.023 Gy/GBq和0.043±0.022 Gy/GBq。
  • 骨转移患者椎体与髋骨红骨髓吸收剂量分别为0.085±0.046 Gy/GBq和0.069±0.033 Gy/GBq。
  • 肿瘤消除快的患者红骨髓消除相统计学上更慢,与177Lu经转铁蛋白转运回红骨髓相符。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bone marrow suppression is a common side effect after [177Lu]Lu-DOTATATE treatment of neuroendocrine neoplasms. Neuroendocrine neoplasms share expression of somatostatin receptor type 2 with CD34-positive hematopoietic progenitor cells, potentially leading to active uptake in the radiosensitive red marrow region where these cells are located. This study aimed to identify and quantify specific red marrow uptake using SPECT/CT images collected after the first treatment cycle. Methods: Seventeen patients diagnosed with neuroendocrine neoplasms were treated with [177Lu]Lu-DOTATATE. Seven of them had confirmed bone metastases. After the first treatment cycle, each patient went through 4 SPECT/CT imaging sessions 4, 24, 48, and 168 h after administration. Monte Carlo-based reconstructions were used to quantify activity concentrations in tumors and multiple skeletal sites presumed to house red marrow: the T9-L5 vertebrae and the ilium portion of the hip bones. The activity concentration from the descending aorta was used as input in a compartment model intended to establish a pure red marrow biodistribution by separating the nonspecific blood-based contribution from the specific activity concentration in red marrow. The biodistributions from the compartment model were used to perform red marrow dosimetry at each skeletal site. Results: Increased uptake of [177Lu]Lu-DOTATATE was observed in the T9-L5 vertebrae and hip bones in all 17 patients compared with activity concentrations in the aorta. The mean specific red marrow uptake was 49% (range, 0%-93%) higher than the nonspecific uptake. The median (±SD) total absorbed dose to the red marrow was 0.056 ± 0.023 Gy/GBq and 0.043 ± 0.022 Gy/GBq for the mean of all vertebrae and hip bones, respectively. The patients with bone metastases had an absorbed dose of 0.085 ± 0.046 Gy/GBq and 0.069 ± 0.033 Gy/GBq for the vertebrae and hip bones, respectively. The red marrow elimination phase was statistically slower in patients with fast tumor elimination, which is in line with transferrin transport of 177Lu back to the red marrow. Conclusion: Our results suggest that specific red marrow uptake of [177Lu]Lu-DOTATATE is in line with observations of somatostatin receptor type 2-expressing hematopoietic progenitor cells within the bone marrow. Blood-based dosimetry methods fail to account for the prolonged elimination of specific uptake and underestimate the absorbed dose to red marrow.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hemmingsson J, Svensson J, Hallqvist A, et al. Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment. J Nucl Med. 2023. PMID: 37290797. doi:10.2967/jnumed.123.265484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。